Novartis AG ( (NVS) ) has released its Q1 earnings. Here is a breakdown of the information Novartis AG presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Novartis AG is a leading global healthcare company based in Switzerland, specializing in innovative medicines across key therapeutic areas such as cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. The company is renowned for its strong pipeline and commitment to advancing healthcare solutions worldwide.
Novartis has reported a robust financial performance in the first quarter of 2025, marked by a 15% increase in net sales at constant currencies and a 27% rise in core operating income. The company attributes this growth to the strong performance of its priority brands, including Entresto, Kisqali, and Kesimpta, alongside significant innovation milestones and regulatory approvals.
Key financial highlights include a 44% increase in operating income and a 66% surge in free cash flow, reaching USD 3.4 billion. Novartis also achieved notable regulatory approvals for new treatments such as Pluvicto and Vanrafia, and completed global submissions for remibrutinib. The company’s strategic focus on expanding its innovative medicines portfolio and enhancing its R&D capabilities continues to drive its growth trajectory.
Looking ahead, Novartis has raised its full-year 2025 guidance, expecting high single-digit growth in net sales and low double-digit growth in core operating income. The company remains committed to its strategic priorities, including accelerating growth, delivering returns, and strengthening its foundations to maintain its leadership in the pharmaceutical industry.